HIV / AIDS

Update on HIV/AIDS HIV-1 is a more dangerous virus than HIV-2: AIDS developed in 54% of people with HIV-1 and 43% of people with HIV-2. After eight years, half of those with HIV-1 had died. In comparison, after 15 years, half of those with HIV-2 had died. The Food and Drug Administration (FDA) recently announced the approval of Dovato, the first complete two-drug HIV treatment regimen for people who previously have not been on antiretroviral therapy. Why is Dovato significant? It offers the potential for these people to take their two-drug regimen in one single tablet. PrEP: Truvada is a brand-name prescription medication that's used for treating HIV infection. It's also used for preventing HIV infection in people who have a high risk of getting HIV. This use, in which the treatment is given before the person may be exposed to HIV, is called pre-exposure prophylaxis (PrEP). Antiretroviral therapy may soon be obsolete, as scientists have successfully used immune cells to kick the dormant form of HIV out of its hiding place and destroy it. The findings may soon lead to an HIV vaccine. Main Points: PrEP works HIV can be detected within weeks Late testing can be lethal Undetectable viral load can be an effective HIV prevention Repeated exposures increase the risk of an activity Not every HIV exposure leads to an infection Rectal fluid can transmit HIV People aren’t using condoms correctly People with AIDS can have a near-normal life expectancy Prepare for an aging HIV epidemic ______ Make sure to subscribe to get the latest episode. Contact Us: Pharmacy Benefit News: http://www.propharmaconsultants.com/pbn.html Email: [email protected] Website: http://www.propharmaconsultants.com/ Facebook: https://www.facebook.com/propharmainc Twitter: https://twitter.com/ProPharma/ Instagram: https://www.instagram.com/propharmainc/ LinkedIn: https://www.linkedin.com/company/pro-pharma-pharmaceutical-consultants-inc/ Podcast: https://anchor.fm/pro-pharma-talks